Michael Burgess

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

Alan Sandler, Michael A. Gordon, Dinesh P. de Alwis et al. · Clinical Cancer Research · 2004 · 151 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Denis Talbot, Malcolm Ranson, J.N.P. Davies et al. · Clinical Cancer Research · 2010 · 98 citations

Medicine, Oncology, Pharmacology +17

Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

Franck Morschhauser, Pier Luigi Zinzani, Michael Burgess et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 81 citations

Medicine, Oncology, Pharmacology +16

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

Sophie Callies, Dinesh P. de Alwis, James G. Wright et al. · Cancer Chemotherapy and Pharmacology · 2003 · 40 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)

Sophie Callies, Dinesh P. de Alwis, Atul Mehta et al. · Cancer Chemotherapy and Pharmacology · 2004 · 31 citations

Pharmacy, Pharmacokinetics, Pharmacology +12